Triple Therapy Boosts Anaplastic Thyroid Cancer Survival

With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.

Related Keywords

United States ,Tampa ,Florida ,Texas ,Washington ,Houston ,American ,Sarah Hamidi ,Mariae Cabanillas ,Sarimar Agosto Salgado ,H Lee Moffitt Cancer Center ,Department Of Head ,Research Institute ,Department Of Endocrine Neoplasia ,Md Anderson Cancer Center ,American Thyroid Association ,University Of Texas Md Anderson Cancer Center ,Drug Administration ,Endocrine Neoplasia ,Hormonal Disorders ,Cancer Center ,Medscape Medical ,Endocrine Oncology ,Moffitt Cancer Center ,Thyroid Cancer ,Thyroid Carcinoma ,Ancer Of The Thyroid ,Malignant Head And Neck Neoplasm ,Thyroid Disorder ,Anaplastic Thyroid Carcinoma ,Naplastic Carcinoma Of The Thyroid ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Skin Cancer ,Alignant Skin Neoplasm ,Toxicology ,Cancer ,Alignant Neoplasia ,Arcinoma ,Thyroid ,Biologic Therapy ,Neoadjuvant ,Kbraf ,Melanoma ,Malignant Melanoma ,Braf Inhibitors ,B Raf Inhib ,